DrugPatentWatch Database Preview

Pegcetacoplan - Generic Drug Details

« Back to Dashboard

What are the generic sources for pegcetacoplan and what is the scope of patent protection?

Pegcetacoplan is the generic ingredient in one branded drug marketed by Apellis Pharms and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pegcetacoplan has one hundred and twenty-one patent family members in twenty-two countries.

Summary for pegcetacoplan

International Patents:	121
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	5
What excipients (inactive ingredients) are in pegcetacoplan?	pegcetacoplan excipients list
DailyMed Link:	pegcetacoplan at DailyMed

Recent Clinical Trials for pegcetacoplan

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Roswell Park Cancer Institute	Phase 2
Apellis Pharmaceuticals, Inc.	Phase 3
Apellis Pharmaceuticals, Inc.	Phase 2

See all pegcetacoplan clinical trials

US Patents and Regulatory Information for pegcetacoplan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apellis Pharms	EMPAVELI	pegcetacoplan	SOLUTION;SUBCUTANEOUS	215014-001	May 14, 2021		RX	Yes	Yes
Apellis Pharms	EMPAVELI	pegcetacoplan	SOLUTION;SUBCUTANEOUS	215014-001	May 14, 2021		RX	Yes	Yes				Y
Apellis Pharms	EMPAVELI	pegcetacoplan	SOLUTION;SUBCUTANEOUS	215014-001	May 14, 2021		RX	Yes	Yes				Y
Apellis Pharms	EMPAVELI	pegcetacoplan	SOLUTION;SUBCUTANEOUS	215014-001	May 14, 2021		RX	Yes	Yes				Y

International Patents for pegcetacoplan

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2007062249
Spain	2526981
Hong Kong	1124621
Australia	2006318333